Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan OKs FY2022 Budget Guidelines, 660 Billion Yen Cap for Social Security Cost Rise
July 8, 2021
- MHLW Announces 1st Revision of Dyslipidemia Drug Development Guidelines in 30 Years
July 8, 2021
- Label Revisions Ordered for Myocarditis/Pericarditis Risks of Pfizer, Moderna’s COVID Vaccines
July 8, 2021
- MHLW’s COVID-19 Guide Recommends against Camostat after Trial Failures
July 7, 2021
- Health Minister Hints at Priority Vaccine Supply to Municipalities Making Headway
July 7, 2021
- MHLW Ups Ante for Regulatory Reviews of Jointly Developed Generics
July 7, 2021
- Leigh Syndrome Drug PTC743 Gets Orphan Status
July 6, 2021
- Draft Revision of MHLW’s Distribution Guidelines Stresses Compliance with Antitrust Act
July 5, 2021
- Govt to Provide Vaccines for All Workplace Programs Requested
July 5, 2021
- MHLW Urges Wholesalers to Strictly Enforce Legal Compliance after Bid-Rigging Ruling
July 2, 2021
- Sakigake Tag Revoked for Eisai’s E7090 after Pemazyre Approval
July 1, 2021
- Vaccines for All People to Be Delivered to Local Govts by October-End: Kono
June 30, 2021
- MHLW to Start Study on US, European Schemes on ADR Evaluation
June 29, 2021
- MHLW Extends Maximum Biz Suspension Period to 180 Days in All Prefectures
June 29, 2021
- Japan Issues Guidelines on Drug Delivery by Drones; Operation Plan, Quality Assurance Required
June 28, 2021
- Japan Allots 33 Million Moderna Shots to Companies, 17 Million to Local Govts: Minister
June 28, 2021
- PMDA Reviewing New Safety Risk for Evenity, 13 Other APIs
June 28, 2021
- MHLW Announces Recommendation for Cannabis Drug Debate
June 28, 2021
- Japan Approves Verquvo, Evrysdi, 2 CGRP Migraine Meds and More
June 24, 2021
- Japan to Stop Accepting Requests for Moderna Vaccines for Workplace Inoculations
June 24, 2021
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…